Search Results - "Raphael, Ari"

  • Showing 1 - 15 results of 15
Refine Results
  1. 1

    Oncologic patients' misconceptions may impede enrollment into clinical trials: a cross-sectional study by Asher, Nethanel, Raphael, Ari, Wolf, Ido, Pelles, Sharon, Geva, Ravit

    Published in BMC medical research methodology (07-01-2022)
    “…Clinical trials are an essential source for advances in oncologic care, yet the enrollment rate is only 2-4%. Patients' reluctance to participate is an…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Valvular Heart Disease following Anthracycline Therapy-Is It Time to Look beyond Ejection Fraction? by Zahler, David, Arnold, Joshua H, Bar-On, Tali, Raphael, Ari, Khoury, Shafik, Rozenbaum, Zach, Banai, Shmuel, Arbel, Yaron, Topilsky, Yan, Laufer-Perl, Michal

    Published in Life (Basel, Switzerland) (20-08-2022)
    “…The association between anthracycline (ANT) and left ventricle (LV) dysfunction is well known; however, data regarding its direct effect on cardiac valve…”
    Get full text
    Journal Article
  4. 4

    GENOMIC PROFILING IN LUMINAL BREAST CANCER by Raphael, Ari, Sonnenblick, Amir

    Published in הרפואה (01-02-2022)
    “…Genomic profiling of breast cancer, with the use of microarrays shows that breast cancer is a group of different diseases. For example, estrogen receptor (ER)…”
    Get more information
    Journal Article
  5. 5

    Body composition measures as a determinant of alpelisib-related toxicity by Shachar, Eliya, Raphael, Ari, Katz, Uriel, Kessner, Rivka, Strulov Shachar, Shlomit

    Published in Journal of clinical oncology (01-06-2024)
    “…e13093 Background: Body composition has emerged as an important prognostic factor in patients treated with cancer. Severe depletion of skeletal muscle,…”
    Get full text
    Journal Article
  6. 6

    Body composition measures as a determinant of Alpelisib related toxicity by Shachar, Eliya, Raphael, Ari, Katz, Uriel, Kessner, Rivka, Shachar, Shlomit Strulov

    Published in Breast cancer research and treatment (01-07-2024)
    “…Background Body composition has emerged as an important prognostic factor in patients treated with cancer. Severe depletion of skeletal muscle, sarcopenia, has…”
    Get full text
    Journal Article
  7. 7

    Abstract P5-13-19: Sarcopenia and skeletal muscle density as predictors of toxicity in patients with metastatic breast cancer receiving alpelisib by Raphael, Ari, Kessner, Rivka, Raphael, Rebeka, Sonnenblick, Amir, Shachar, Shlomit Strulov

    Published in Cancer research (Chicago, Ill.) (15-02-2022)
    “…Abstract Background: Poor body composition metrics (BCM) are associated with inferior cancer outcomes. Alpelisib, a PIK3CA inhibitor, is increasingly used in…”
    Get full text
    Journal Article
  8. 8

    Body composition measures as predictors of toxicity in patients with metastatic breast cancer receiving PARP inhibitors by Etan, Tal, Kessner, Rivka, Peleg Hasson, Shira, Raphael, Ari, Sonnenblick, Amir, Zlothover, Noa, Epstein, Jessica, Shachar, Shlomit Strulov

    Published in Journal of clinical oncology (01-06-2023)
    “…e13010 Background: Poor body composition metrics (BCM), such as high adiposity or low muscle mass, are associated with inferior cancer outcomes. Poly…”
    Get full text
    Journal Article
  9. 9
  10. 10

    High neutrophil‐to‐lymphocyte ratio as an early sign of cardiotoxicity in breast cancer patients treated with anthracycline by Baruch, Ranny, Zahler, David, Zornitzki, Lior, Arbel, Yaron, Rozenbaum, Zach, Arnold, Joshua H., Raphael, Ari, Khoury, Shafik, Banai, Shmuel, Topilsky, Yan, Kapusta, Livia, Laufer‐Perl, Michal

    Published in Clinical cardiology (Mahwah, N.J.) (01-03-2023)
    “…Background Cardiotoxicity, defined mainly as left ventricle (LV) dysfunction, is a significant side effect of anthracyclines (ANT) therapy. The need for an…”
    Get full text
    Journal Article
  11. 11

    Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment by Raphael, Ari, Salmon-Divon, Mali, Epstein, Jessica, Zahavi, Tamar, Sonnenblick, Amir, Shachar, Shlomit S

    Published in Genes (29-09-2022)
    “…This real-world cohort analysis assessed the efficacy of alpelisib and endocrine treatment (ET) combinations in a post-everolimus setting. Thirteen women who…”
    Get full text
    Journal Article
  12. 12

    Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis by Peleg Hasson, Shira, Salwen, Benjamin, Sivan, Ayelet, Shamai, Sivan, Geva, Ravit, Merimsky, Ofer, Raphael, Ari, Shmilovich, Haim, Moshkovits, Yonatan, Kapusta, livia, Rozenbaum, Zach, Wolf, Ido, Laufer-Perl, Michal

    Published in Clinical research in cardiology (2021)
    “…Background Immune checkpoint inhibitors (ICI) have transformed the standard care of cancer treatment. Recent case reports describe ICI-mediated myocarditis…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15